Flexible Therapeutic Development: Balancing Speed, Cost, and Process

Explore how KBI Biopharma delivers fast, cost-effective, and robust microbial protein process development, tailored for first-in-human (FIH, Phase I) programs and adaptable to each client’s needs for speed, cost, and performance.

Learning Objectives:
– Key considerations for microbial cell line, fermentation, and purification development for FIH
– How milestones align from proof-of-concept to toxicology material
– How platform-based and robotic workflows can optimize cost, speed, or robustness—no license fee required